ArticleImmunotherapy2021

Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.

Shaukat Ali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.